QURE
uniQure N.V.
6.98
USD
This page is just a preview of the data found in TrendSpider’s full version
uniQure N.V. stock is up 22.89% since 30 days ago. The next earnings date is Feb 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 80% of the previous 9 November’s closed higher than October. In the last 5 Unusual Options Trades, there were 2 PUTs, 3 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 02 Oct 13:53 | 19 Jan, 2024 | 7.50 | 677 | ||
| 03 Oct 18:27 | 19 Jan, 2024 | 7.50 | 273 | ||
| 19 Oct 15:32 | 19 Jan, 2024 | 22.50 | 0 | ||
| 23 Oct 16:46 | 19 Jan, 2024 | 35.00 | 23 | ||
| 27 Nov 18:30 | 19 Jan, 2024 | 7.50 | 3456 |
uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.
